Targets › APOL1
2 programs from 2 companies in 2 trials: 2 Phase 2; Genitourinary; next expected readout Oct 2027.
May play a role in lipid exchange and transport throughout the body. May participate in reverse cholesterol transport from peripheral cells to the liver. (UniProt, O14791)
Open in Phaseline: the race on APOL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | AZD2373 APOL1-mediated kidney disease inhibitor | APOL1 | Phase 2 | APOL1-Mediated Kidney Disease | Oct 2027 |
| Vertex Pharmaceuticals | VX-147 APOL1 inhibitor | APOL1 | Phase 2 | Proteinuric Kidney Disease | Jun 2028 |
APOL1-Mediated Kidney Disease (1) Proteinuric Kidney Disease (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.